Explorez tous les épisodes du podcast Keeping Current
| Titre | Date | Durée | |
|---|---|---|---|
| Solving the Alzheimer's Disease Biomarker Puzzle: Live, European Peer Workshop | 28 Sep 2026 | 00:36:28 | |
Do you know who to test, when to test, and which biomarker test to use? Credit available for this activity expires: 9/28/27 | |||
| Advancing Uveitic Macular Edema Management: What's New? | 28 Sep 2026 | 00:32:09 | |
Do you know how to meet the challenges of treating uveitic macular edema? Credit available for this activity expires: 9/28/27 | |||
| Patient Journeys With IgA Nephropathy: Optimizing Outcomes in Patient Care | 25 Sep 2026 | 00:59:36 | |
Move beyond supportive care with targeted therapies for immunoglobulin A nephropathy (IgAN) management. Credit available for this activity expires: 09/24/2027 | |||
| Refining Adjuvant Therapy in HR-Positive/HER2-Negative Early Breast Cancer: Personalizing Care in the CDK4/6 Inhibitor Era | 24 Sep 2026 | 00:52:11 | |
How can adjuvant therapy be optimally individualized? What tools and insights are required? Join us to learn more. Credit available for this activity expires: 09/21/2027 | |||
| The Patient Journey With Severe Refractory Autoimmune Rheumatic Diseases: Exploring the Potential for CAR T-Cell Therapies | 22 Sep 2026 | 00:48:44 | |
Can CAR T-cell therapies achieve drug-free remission in severe refractory autoimmune diseases? Credit available for this activity expires: 9/22/27 | |||
| Translating Molecular Insights Into Practice for HR-Positive/HER2-Negative Metastatic Breast Cancer | 22 Sep 2026 | 00:35:38 | |
Are you up to speed on the latest updates on molecular-guided therapies in HR-positive/HER2-negative metastatic breast cancer (MBC)? Join us to learn more. Credit available for this activity expires: 9/18/27 | |||
| Targeting the Metabolic Driver: A Forward-Looking Approach to Obesity and Liver Health | 08 Sep 2026 | 00:29:23 | |
Discover how emerging targeted therapies address systemic drivers in MASLD and MASH. Credit available for this activity expires: 9/8/27 | |||
| The Whole Patient: Integrating the Lived Experience of Myasthenia Gravis | 04 Sep 2026 | 00:42:15 | |
Fatigue, unpredictability, and life goals; integrate what patients say they need into how you treat myasthenia gravis (MG). Credit available for this activity expires: 9/4/27 | |||
| Epilepsy in General Neurology Practice: Optimizing a Therapeutic Approach From the Start | 01 Sep 2026 | 00:47:35 | |
Are your epilepsy patients achieving true seizure freedom, or is it time to adjust their therapy? Credit available for this activity expires: 9/1/27 | |||
| Myasthenia Gravis Guidelines: A Global View for Local Practice | 19 Aug 2026 | 00:38:12 | |
Compare global myasthenia gravis (MG) guidelines to optimize local, patient-centered treatment pathways. Credit available for this activity expires: 8/17/27 | |||
| From Mechanism to Management: Applying Evidence for Hemophilia A in the Clinic | 18 Aug 2026 | 00:18:01 | |
Are non-factor therapies enough to protect your hemophilia A patients during surgery? Credit available for this activity expires: 8/18/27 | |||
| Updating Our Checklist for Transthyretin Amyloid Cardiomyopathy Monitoring | 14 Aug 2026 | 00:41:36 | |
Master multimodality imaging and autonomic red flag screening in your transthyretin amyloid cardiomyopathy (ATTR-CM) practice. Episode learning points & Disclosures: https://www.medscape.org/viewarticle/updating-our-checklist-transthyretin-amyloid-cardiomyopathy-2026a1000pul?ecd=bdc_podcast_libsyn_mscpedu | |||
| Mild Cognitive Impairment and Mild Dementia: Can We Act Before It's Too Late? | 07 Aug 2026 | 00:39:21 | |
What tests are best to assess early cognitive symptoms? Credit available for this activity expires: 03/05/2027 | |||
| Why Target APRIL in IgA Nephropathy Management? Get Up to Speed With the Mechanisms of Action and Key Data | 05 Aug 2026 | 00:27:56 | |
Explore emerging B-cell-targeted therapies for immunoglobulin A nephropathy (IgAN). Unpack novel mechanisms of action (MOAs) and the latest clinical data to protect kidneys now. Credit available for this activity expires: 8/5/27 | |||
| Beyond Intervals: The Next Era of Continuous Delivery in Retinal Medicine | 24 Jul 2026 | 00:32:28 | |
Are you up to date on developments in technology for treating retinovascular disease? Credit available for this activity expires: 7/24/27 | |||
| When and How Should I Optimize Heart Failure Treatments for My Patients? | 23 Jul 2026 | 00:26:07 | |
Gain expert insights on how best to implement GDMT for your patients in the transition from hospitalization to post-discharge. Credit available for this activity expires: 7/22/27 | |||
| The Evolving Diagnostic and Management Landscape for Progressive Familial Intrahepatic Cholestasis | 21 Jul 2026 | 00:35:35 | |
Update PFIC care, from genetic diagnosis to guideline-recommended management. Credit available for this activity expires: 7/21/27 | |||
| Pharmacological and Combination Interventions for Nicotine Cessation | 30 Jun 2026 | 00:33:24 | |
Master the latest evidence-based meds and dual therapies to help your patients quit for good. Credit available for this activity expires: 06/25/2027 | |||
| Is Normalizing Hemostasis an Achievable Goal in Hemophilia A? | 26 Jun 2026 | 00:29:31 | |
Is sustained hemostatic normalization achievable across all hemophilia A patients? Examine the evidence behind today's therapeutic advances. Credit available for this activity expires: 6/26/27 | |||
| The Top 5 Errors in Transthyretin Amyloid Cardiomyopathy Management | 26 Jun 2026 | 00:17:41 | |
Drs García-Pavia and Sperry break down the top 5 mistakes in transthyretin amyloid cardiomyopathy (ATTR-CM) management and share clinical solutions for earlier, optimized patient care. Credit available for this activity expires: 6/25/27 | |||
| Better Drying? Longer Lasting? Second-Generation Anti-VEGF Therapies in Clinical Practice | 23 Jun 2026 | 00:37:03 | |
Learn to optimize durability and drying with new second-generation anti-VEGF therapies. Credit available for this activity expires: 6/19/27 | |||
| Shaping the Future of Precision Oncology: Biomarker-Driven Care for Tumor-Agnostic Therapies | 17 Jun 2026 | 00:23:21 | |
Do you know how tumor-agnostic therapies are helping to reshape cancer treatment pathways? Credit available for this activity expires: 6/16/27 | |||
| Navigating the Management of Alagille Syndrome Using Ileal Bile Acid Transporter (IBAT) Inhibitors | 17 Jun 2026 | 00:21:55 | |
Which patients with Alagille syndrome benefit from IBAT inhibitors, and what should you watch for during therapy? Credit available for this activity expires: 6/16/27 | |||
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy Care Partnerships: Aligning Goals for Better Outcomes | 05 Jun 2026 | 00:26:15 | |
How does it feel to live with CIDP? Bridge the gap between metrics and patient reality. Align goals and improve outcomes via shared decision-making. Credit available for this activity expires: 6/4/27 | |||
| The Molecular Nuances of Hemostasis: Differentiating FVIII and Non-Factor Replacement | 02 Jun 2026 | 00:29:13 | |
Do you know how the different therapies act in hemophilia A? Credit available for this activity expires: 05/29/2027 | |||
| Depression and Neurological Diseases: What's the Link? | 01 Jun 2026 | 00:22:29 | |
Can you untangle the threads linking depression and neurological disease to effectively treat your patients? Credit available for this activity expires: 06/01/2027 | |||
| What Lies Beneath Generalized Myasthenia Gravis: Exploring Novel Mechanisms of Action of Emerging Therapies | 21 May 2026 | 00:31:16 | |
What is lacking in the care of your patients with myasthenia gravis? Find out how novel pathology-targeting therapies can meet unmet needs. Credit available for this activity expires: 5/19/27 | |||
| Charting New Frontiers in Advanced Breast Cancer: Milestones, Missions, and Mastery | 21 May 2026 | 01:16:10 | |
What do the latest clinical trial data tell us and how do they impact practice? Credit available for this activity expires: 5/20/27 | |||
| Beyond SGLT2: The Emerging Role of Dual SGLT1/2 Inhibition in Heart Failure | 18 May 2026 | 00:29:49 | |
Discover how dual sodium-glucose cotransporter 1/2 (SGLT1/2) inhibition can improve outcomes for your patients across the heart failure (HF) spectrum. Credit available for this activity expires: 05/15/27 | |||
| Addressing Unmet Needs in the Management of Sjögren's Disease: A Spotlight on Emerging Biologic Therapies | 14 May 2026 | 00:30:40 | |
Keep up with the move toward targeted disease modifying therapies in Sjögren's disease. Credit available for this activity expires: 05/12/27 | |||
| Challenges and Opportunities in the Diagnostic Pathway for Biliary Atresia | 01 May 2026 | 00:35:33 | |
Recognize biliary atresia (BA) signs early to stop pediatric liver transplant. Gain expert insights on screening, diagnosis, and urgent referral pathways. Credit available for this activity expires: 05/01/2027 | |||
| Diabetic Macular Edema: Express Q&A on What's New | 30 Apr 2026 | 00:16:57 | |
Improve real-world DME outcomes by mastering the interpretation of evolving biomarkers and the latest evidence on long-acting anti-VEGF therapies. Credit available for this activity expires: [04/28/27] | |||
| The Science of SGLT1 and SGLT2: Unpacking Dual Inhibition for Heart Failure | 13 Apr 2026 | 00:17:14 | |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors transformed HF care. Meet SGLT1, a transporter that may unlock even greater CV protection. Credit available for this activity expires: 4/10/27 | |||
| Liver Fibrosis in Type 2 Diabetes and Obesity: A Case-Based Approach | 30 Mar 2026 | 00:21:05 | |
Intervening early can stop metabolic dysfunction-associated steatohepatitis (MASH) progressing to fibrosis. Which of your patients with type 2 diabetes (T2D) or obesity need treatment, and what therapies are available? Credit available for this activity expires: 3/26/27 | |||
| Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer | 23 Mar 2026 | 00:36:15 | |
Where do PI3K/AKT pathway inhibitors fit in the modern treatment landscape of breast cancer? Credit available for this activity expires: 3/19/2027 | |||
| New Horizons in Uveitic Macular Edema | 18 Mar 2026 | 00:33:32 | |
Do you know when to suspect edema in uveitis and how to manage it? Credit available for this activity expires: 3/18/27 | |||
| Metabolic Crossroads: Navigating the Obesity–Liver Disease Axis | 18 Mar 2026 | 00:51:20 | |
Do you know how to optimally identify, risk stratify, and treat your patients with obesity and MASLD or MASH? Credit available for this activity expires: 03/17/2027 | |||
| Beyond the Update in Advanced/Recurrent Endometrial Cancer: How Evidence Is Shaping New Guidelines | 11 Mar 2026 | 00:37:09 | |
What clinical trials led to updates in the treatment strategies for advanced/recurrent endometrial cancer? Credit available for this activity expires: 3/9/27 | |||
| Beyond PSMA: Preparing Your Practice for the Next Wave of Prostate Cancer Biomarkers | 10 Mar 2026 | 00:31:04 | |
Are you up to speed on emerging biomarkers? Join our expert panel to learn more about their clinical relevance and testing best practices Credit available for this activity expires: 3/6/27 | |||
| Avoiding Common Mistakes in Managing Focal Epilepsy | 05 Mar 2026 | 00:19:08 | |
Do you know how many seizures is too many? Or what drugs to avoid in older epilepsy patients? Credit available for this activity expires: 3/3/27 | |||
| From Prescription to Practice in Respiratory Diseases: Overcoming Barriers to Inhaler Adherence and Compliance | 27 Feb 2026 | 00:35:16 | |
Are you optimizing inhaler choice and technique to achieve better outcomes? Credit available for this activity expires: 2/27/27 | |||
| The CLL Consultation: Partnering With Patients for Person-Centred Care | 27 Feb 2026 | 00:35:34 | |
Do you know how person-centred care can help address the challenges faced by chronic lymphocytic leukaemia (CLL) patients? | |||
| Immunotherapy for Non-Muscle-Invasive Bladder Cancer: Expert Takeaways From the Latest Updates | 27 Feb 2026 | 00:37:26 | |
Did you know that combining Bacillus Calmette-Guérin (BCG) with immunotherapy significantly improves outcomes in high-risk bladder cancer? Credit available for this activity expires: 2/24/27 | |||
| Navigating the HER2 Spectrum in Breast Cancer: Evolving Diagnostic Paradigms for Clinical Excellence | 19 Feb 2026 | 00:33:46 | |
Are you up to date on HER2 testing best practices? Join our expert panel and discover the critical updates that guide treatment selection. Credit available for this activity expires: 2/17/27 | |||
| 2025 Winter Conference Update: Novel and Emerging Treatment Strategies for Breast Cancer | 06 Feb 2026 | 00:36:58 | |
What do the latest data from the 2025 breast cancer Winter Conference tell us? Credit available for this activity expires: 02/02/2027 | |||
| A Case-Based Journey From Risk to Results | 02 Feb 2026 | 00:18:36 | |
Known as a "silent" disease because it has few or no symptoms, MASH increases cirrhosis, cancer, and death rates despite being both detectable and treatable. Credit available for this activity expires: 01/30/2027 | |||
| HER2-Positive Early Breast Cancer: What the Latest Data Mean for Your Practice | 30 Jan 2026 | 00:18:50 | |
Are you up-to-date on the latest data in HER2-positive early breast cancer? Join our experts as they discuss the data and the clinical implications! Credit available for this activity expires: 01/29/2027 | |||
| Balancing ART and Comorbidities in Aging People Living With HIV | 20 Jan 2026 | 00:27:04 | |
How can we optimize ART in people living with HIV while addressing comorbidities and minimizing toxicity? Credit available for this activity expires: 01/15/27 | |||
| The Alarming Carbon Footprint of Respiratory Disease: The Future of Sustainable Inhaler Technology | 05 Jan 2026 | 00:33:17 | |
Low-carbon inhalers: Are you finding the right balance for optimal patient care and planetary health? Credit available for this activity expires: 12/31/26 | |||
| Achieving Brain Health in Epilepsy: What Can Clinicians Do? | 05 Jan 2026 | 00:21:00 | |
Are you asking about sleep, activity levels, and mood? Why you should be and what to do next. Credit available for this activity expires: 12/31/26 | |||